New treatment approach for difficult-to-treat multiple myeloma
Novel Mcl-1 Inhibitor for Combination Treatment of Refractory Multiple Myeloma
['FUNDING_R15'] · ROWAN UNIVERSITY · NIH-10974902
This study is testing a new drug called KS18 that aims to help patients with multiple myeloma, especially those whose cancer hasn't responded to other treatments, by working alongside existing therapies to better fight the disease and prevent it from coming back.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROWAN UNIVERSITY (nih funded) |
| Locations | 1 site (GLASSBORO, UNITED STATES) |
| Trial ID | NIH-10974902 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel inhibitor targeting Mcl-1, a protein that helps multiple myeloma cells survive despite treatment. The study aims to explore how this new drug, KS18, can be combined with existing therapies to effectively kill resistant myeloma cells and prevent relapse. Patients with multiple myeloma who have experienced treatment resistance may benefit from this approach. The research will involve laboratory studies and may lead to clinical trials for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with multiple myeloma who have not responded to standard treatments.
Not a fit: Patients with early-stage multiple myeloma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with refractory multiple myeloma, potentially improving survival rates.
How similar studies have performed: While some studies have explored Mcl-1 inhibitors, this specific approach with KS18 is novel and has not been widely tested in clinical settings.
Where this research is happening
GLASSBORO, UNITED STATES
- ROWAN UNIVERSITY — GLASSBORO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PANDEY, MANOJ KUMAR — ROWAN UNIVERSITY
- Study coordinator: PANDEY, MANOJ KUMAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents